For the millions navigating addiction recovery, the tools most accessible — breath — may carry more therapeutic weight than commonly assumed. A rigorous meta-analysis now quantifies what clinicians have long suspected anecdotally: structured breathing practices and heart rate variability biofeedback (HRVB) produce measurable, statistically significant reductions in craving across alcohol, drugs, and nicotine use disorders, potentially reshaping how adjunct therapies are integrated into standard care.
Drawing from 3,502 screened studies and ultimately synthesizing data from 15 eligible trials (out of 20 meeting full inclusion criteria), this systematic review — registered prospectively with PROSPERO and following PRISMA guidelines — applied a random-effects model to pool outcomes. Breathing-based interventions, categorized by whether they incorporated HRVB technology, consistently outperformed control conditions on craving-related outcomes. The effect size was characterized as small but statistically significant and consistent, an important distinction in addiction research where even modest reductions in craving can meaningfully alter relapse trajectories. Substances studied included alcohol, nicotine, and other drugs, broadening the generalizability of findings beyond a single-substance focus.
This analysis arrives at a moment when the field is actively seeking scalable, low-cost adjuncts to pharmacological and behavioral therapies. HRVB, which trains individuals to modulate autonomic nervous system function through paced breathing at resonance frequency (typically around 0.1 Hz), has a growing mechanistic basis — it engages vagal tone, prefrontal cortical inhibition, and interoceptive awareness, all of which are dysregulated in addiction. The finding that even simpler controlled breathing without biofeedback hardware produced benefits suggests a dose-response continuum worth exploring further. Key limitations include the small pool of eligible studies (n=20), probable heterogeneity in intervention protocols, and the typically short follow-up periods common in behavioral trials. This is best characterized as a confirmatory, momentum-building analysis — not yet practice-changing on its own, but a compelling evidence base justifying larger, better-controlled trials.